Pharma Business - August 11, 2017
Novo’s Victoza has been approved in the EU
The European Commission has approved an update to the Victoza (liraglutide) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment. Victoza is the only GLP-1 that is proven to prevent CV events in people with type 2 diabetes and high […]
Clinical Trials - June 11, 2016
Novo’s Victoza reduce risk of major cardiovascular events
Novo Nordisk has announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to standard of care in 9,340 adults with type 2 diabetes at high CV […]
Clinical Trials - June 8, 2015
Novo Drug Works During Ramadan Fast
Adults with type 2 diabetes treated with Novo Nordisk’s Victoza®, in combination with metformin, experienced similar improvements in blood glucose control while fasting during the four weeks of Ramadan compared with sulfonylurea (SU) plus metformin, according to a recent study. People treated with Victoza® also demonstrated greater weight loss and fewer confirmed hypoglycemic episodes compared with […]
Pharma Business - January 22, 2015
EC Grants Extension to Victoza
The license extension for Novo Nordisk’s Victoza® means the drug is now available to almost one million people in the UK who are affected by type 2 diabetes and moderate renal impairment. The decision by the European Commission (EC) means clinicians can treat patients with one daily injection. providing an effective treatment in an area where few treatments are available […]
Drug Development Pharma - November 24, 2014
CHMP Approves Victoza
The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion for the use of Victoza® (liraglutide) in adults with type 2 diabetes and moderate renal impairment. Once the European Commission approves the label expansion, physicians in the European Union will be able to prescribe Victoza®, a once-daily human glucagon-like peptide-1 (GLP-1) analogue, to […]
